quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Startups Are Still Acquiring Startups, Led By Ultra-High-Valuation Unicorns

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: Startups Are Still Acquiring Startups, Led By Ultra-High-Valuation Unicorns Date: 2026-08-24 11:00 Source: https://news.crunchbase.com/ma/startup-unicorns-acquisitions-ai-fintech-biotech/ <p>For a startup, selling to another startup isn’t the classic exit strategy…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • OpenAI has bought at least 19 companies to date, most of the eight acquired this year being seed- or early-stage companies.

    60% confidence
  • More than 500 seed- or venture-backed private companies across the globe have sold to other private, venture-backed companies so far this year.

    60% confidence
  • There is little indication of an imminent slowdown in startups' appetite for acquisitions, given competition for AI talent and technology, concentration of venture capital, and go-to-market costs.

    60% confidence
  • Reported startup M&A deal counts are down slightly in 2026 versus the comparable period last year, though this is expected to even out as more deals are added to the dataset over time.

    60% confidence

Data points we hold from this source

OpenAI · acquisition count this year8 companies
OpenAI · cumulative acquisition count19 companies
Anthropic · acquisition count this year5 companies
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com